Seagen says new ADCETRIS data to be featured at ASH 2023

Seagen announced that 12- and 24-month progression free survival data will be presented for an ADCETRIS and immunotherapy combination in early and advanced stage classical Hodgkin lymphoma, respectively. The data will be featured in two oral presentations at the 65th American Society of HematologyAnnual Meeting & Exposition, taking place December 9-12, 2023 in San Diego. The ongoing Phase 2 clinical trial, SGN35-027, is evaluating ADCETRIS in combination with immunotherapy and chemotherapy. In addition, pre-clinical data will be presented for a next-generation novel CD30-directed antibody-drug conjugate (ADC), SGN-35C, that uses a topoisomerase I inhibitor payload. “These new data highlight our continued research and development focus on novel combinations to treat Hodgkin lymphoma and on next-generation CD30-directed therapies that aim to further improve outcomes while reducing treatment burden for patients,” said Roger Dansey, M.D., President, Research and Development and Chief Medical Officer at Seagen.